This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
We have written on the value of a creating a globally diverse REIT portfolio before. For those not wanting to go through the trouble, BPY shares accomplish some of that with a single purchase. It is rare to find a real estate company with a dividend yield over 6% with such a superb portfolio. The built in diversification of office, retail and opportunistic investments along with a global portfolio add to the appeal.
TCO.PRK TCO.PRJ GGP TCO GGP.PRA
Between the four REIT team members, we met with over 50 REIT management teams at the June REITWeek conference.
KRC.PRG BPY KRC.PRH DCT KRC BXP TCO KRG UDR LSI TRNO EQR MAC JCAP.PRB AVB REG.PRG REG.PRF VNO EQIX TCO.PRK TCO.PRJ FR FRT JBGS RVI JCAP SPG QTS WPG PEI REG DLR.PRH DLR.PRG DLR.PRJ DLR.PRI SKT CXP EXR CONE COR ESS GGP EGP DDR MNR ROIC UE RPAI PLD SPG.PRJ KRLP OFC IRT BXP.PRB REXR DLR LPT DLR.PRC WRI DLR.PRF ESRT
While investing in dividend champions like Altria Group (MO), Procter & Gamble (PG), and AT&T (T) can be appealing, investors should diversify across several sectors. At The REIT Forum, we specialize in REITs.
BAMGF BPY NLY NLY.PRA NLY.PRECL NLY.PRD SUI.PRA NLY.PRE GGP.PRA NLY.PRC NLY.PRF NLY.PRG SUI AGNC GGP BAMKF BAM MO
The holdings in the ETF are extremely diverse, with the highest weights going to large REITs with strong fundamentals.
REG DLR.PRH KIM.PRI DLR.PRG DLR.PRJ DLR.PRI DRE AMT.PRB STAG.PRB AMT.PRA STAG.PRC TCO KIM.PRM KIM.PRL KIM.PRK KIM.PRJ AMZN AMT ESS CCI.PRA CCI GGP MAC KIM STAG STAG.PRA REG.PRG REG.PRF EQIX TCO.PRK TCO.PRJ DRE.PRO PLD BRX SPG.PRJ T VZ STAG.PRBCL DLR SPG SBAC DLR.PRC WPG DLR.PRF DRE.PRL CBL
REIT headwinds persist, including rising interest rates and bond yields, as well as the pro-growth, risk-on environment.
REG GEO BPY ARI EPR.PRG O.PRF OPRF KRG UMH.PRD UMH.PRC UMH.PRB UMH.PRA AI LADR EQR AI.PRB CORR.PRA GGP UMH AIW AVB CORR REG.PRG REG.PRF ARI.PRA NRZ ARI.PRC AIC O NLY NLY.PRA NLY.PRECL NLY.PRD NLY.PRE GGP.PRA NLY.PRC NLY.PRF NLY.PRG EPR CBL
Merger activity increased last week with two new deals announced and five pending deals closing. Several deals with large spreads on account of regulatory hurdles including Bayer's acquisition of Monsanto, AT&T's (NYSE:T) acquisition of Time Warner and China Oceanwide's acquisition of Genworth (NYSE:GNW) recently managed to get past those hurdles.
CAVM MRVL STDY RAD TWX NXPI WGL SXE MCHP TWC MSCC T CALL GNW QCOM GGP
With market valuations rising substantially in the past year, it has been challenging to identify underperforming assets with attractive entry points. This is not the case with Brookfield Property Partners (NYSE:BPY). BPY remains one of the finest run commercial real estate organizations across the globe after reporting solid first quarter results marked by another y/y increase in cash flow and recycling of capital.
BAMGF BPY GGP BAMKF BAM
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to GGP / GGP, Inc. on message board site Silicon Investor.
|General Growth Properties (GGP)||CSGGP|
|George Resources V.GGP|
as of ET